Solid Biosciences INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Solid Biosciences reports positive interim clinical data for SGT-003 in Duchenne, initiates Phase 3, and secures significant financing to extend its cash runway into mid-2028.
NASDAQ
Solid Biosciences announces positive early data from its INSPIRE DUCHENNE trial and FDA clearance for its Friedreich's ataxia treatment, marking significant progress in its rare disease pipeline.
NASDAQ
Solid Biosciences has introduced a new stock incentive plan aimed at attracting and retaining individuals who can significantly contribute to the company's growth.